Collaborations & Alliances

BMS, Janssen in Immuno-oncology Alliance

Will evaluate Opdivo and Janssen drug in Phase II NSCLC trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb has entered a new clinical research collaboration with Janssen Biotech, Inc. to evaluate BMS’ immuno-oncology drug Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC). Opdivois a human antibody designed to alleviate immune suppression. JNJ-64041757 is designed to induce an immune response against NSCLC tumo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters